MedTrace Logo

Sodium Pyruvate Therapy in COPD Patients

NCT00262613 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2006-05-29

No results posted yet for this study

Summary

In animal models, sodium pyruvate has been shown to be an effective anti-inflammatory agent, and in human studies sodium pyruvate has been shown to be a bronchodilating agent. Subjects with COPD are known to have inflammation in the lung, and often have bronchoconstriction. As such, these subjects typically are on multiple therapies, including steroid therapy. This trial will study the effect of inhaled sodium pyruvate on inflammation and lung function in COPD subjects over a six week period.

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG

sodium pyruvate in 0.9% sodium chloride solution

Sponsors & Collaborators

  • Cellular Sciences, inc.

    collaborator INDUSTRY

  • Emphycorp

    lead INDUSTRY

Principal Investigators

  • John J. Votto, D.O. · Hospital for Special Care

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2004-09-30
Completion
2006-05-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00262613 on ClinicalTrials.gov